NovoCure develops and sells tumor treating fields (TTFields) devices for solid tumor cancer treatment. Its devices include Optune for glioblastoma and Optune Lua for malignant pleural mesothelioma. The company has ongoing or completed clinical trials for TTFields in various cancers. NovoCure is based in Saint Helier, Jersey and operates in the US, Europe, the Middle East, Africa, Japan, and Greater China.